Key Drivers
- Strong liquidity
- High cash conversion
- Elevated R&D/SG&A
AIAI Summary
Alkermes has shifted from a steady psychiatry roll‑up into a hybrid commercial-plus high‑risk R&D company—meaning investors should now treat ALKS as an execution-dependent capital-allocation bet where upside hinges on successful Lumryz commercial integration and binary Phase III/FDA outcomes for alixorexton (monitor FY‑2026 guidance, quarterly FCF, and integration milestones for signs to re-rate or raise equity).
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •High cash conversion
- •Elevated R&D/SG&A
Alkermes shows very strong liquidity, low leverage and high free-cash-flow conversion but heavy R&D/SG&A and uneven quarterly earnings that could pressure operating leverage.
Price Behavior
Key Price Behavior Insights:
- •Short-term downtrend
- •Upper‑$27s support
- •Low‑$30s resistance
Over the last month ALKS rotated from a late‑February peak into a short-term downtrend, trading a few percent below its 21‑day average with support in the upper‑$27s and immediate resistance in the low‑$30s.
Closing price on 2026-03-20 is meaningfully below the last-month average, signaling recent negative momentum
Sentiment & News
Key News Insights:
- •Q4 EPS beat
- •CEO succession
- •Orexin advancement
Alkermes beat Q4 EPS and outlined 2026 growth plans and orexin late‑stage progress but shares dropped after a CEO succession announcement and a cautious sell ranking.
The mix of solid operational updates and leadership transition introduces short-term volatility risk despite longer-term commercial and pipeline upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings